Serum lipid trajectories in the years before a lymphoma diagnosis

References

• Ferlay JE, Lam F, Colombet M, et al. Global cancer observatory: cancer today [homepage on the internet]. Lyon, France: International Agency for Research on Cancer; 2018. https://gco.iarc.fr/today.
   Google Scholar
• Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014(48):130–144.
   PubMedGoogle Scholar
• Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132.
   PubMed Web of Science ®Google Scholar
• Blackman JD, Cabana VG, Mazzone T. The acute-phase response and associated lipoprotein abnormalities accompanying lymphoma. J Intern Med. 1993;233(2):201–204.
   PubMed Web of Science ®Google Scholar
• Chao FC, Efron B, Wolf P. The possible prognostic usefulness of assessing serum proteins and cholesterol in malignancy. Cancer. 1975;35(4):1223–1229.
   PubMed Web of Science ®Google Scholar
• Garg A, Hosfield EM, Brickner L. Disseminated intravascular large B cell lymphoma with slowly decreasing high-density lipoprotein cholesterol. South Med J. 2011;104(1):53–56.
   PubMed Web of Science ®Google Scholar
• Spiegel RJ, Schaefer EJ, Magrath IT, et al. Plasma lipid alterations in leukemia and lymphoma. Am J Med. 1982;72(5):775–782.
   PubMed Web of Science ®Google Scholar
• Kuzu OF, Noory MA, Robertson GP. The role of cholesterol in cancer. Cancer Res. 2016;76(8):2063–2070.
   PubMed Web of Science ®Google Scholar
• Alford SH, Divine G, Chao C, et al. Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis. Cancer Causes Control. 2018;29(1):143–156.
   PubMed Web of Science ®Google Scholar
• Margulis AV, Fortuny J, Kaye JA, et al. Validation of cancer cases using primary care, cancer registry, and hospitalization data in the United Kingdom. Epidemiology. 2018;29(2):308–313.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Hiatt RA, Fireman BH. Serum cholesterol and the incidence of cancer in a large cohort. J Chronic Dis. 1986;39(11):861–870.
   PubMedGoogle Scholar
• Kritchevsky SB, Wilcosky TC, Morris DL, et al. Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Cancer Res. 1991;51(12):3198–3203.
   PubMed Web of Science ®Google Scholar
• Lim U, Gayles T, Katki HA, et al. Serum high-density lipoprotein cholesterol and risk of non-Hodgkin lymphoma. Cancer Res. 2007;67(11):5569–5574.
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Conroy SM, Ollberding NJ, et al. Erythrocyte membrane fatty acid composition, serum lipids, and non-Hodgkin’s lymphoma risk in a nested case-control study: the multiethnic cohort. Cancer Causes Control. 2012;23(10):1693–1703.
   PubMed Web of Science ®Google Scholar
• Nagel G, Stocks T, Spath D, et al. Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Ann Hematol. 2012;91(10):1519–1531.
   PubMed Web of Science ®Google Scholar
• Strasak AM, Pfeiffer RM, Brant LJ, et al. Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: a prospective 19-year follow-up study. Ann Oncol. 2009;20(6):1113–1120.
   PubMed Web of Science ®Google Scholar
• Strohmaier S, Edlinger M, Manjer J, et al. Total serum cholesterol and cancer incidence in the metabolic syndrome and cancer project (Me-Can). ). PLOS One. 2013;8(1):e54242.
   PubMed Web of Science ®Google Scholar
• Ahn J, Lim U, Weinstein SJ, et al. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2814–2821.
   PubMed Web of Science ®Google Scholar
• Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol. 2008;9(2):125–138.
   PubMed Web of Science ®Google Scholar
• Vekic J, Zeljkovic A, Stefanovic A, et al. Obesity and dyslipidemia. Metabolism. 2019;92:71–81.
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836.
   PubMed Web of Science ®Google Scholar
• Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US census bureau data. Perm J. 2012;16(3):37–41.
   PubMedGoogle Scholar
• Mathur R, Bhaskaran K, Chaturvedi N, et al. Completeness and usability of ethnicity data in UK-based primary care and hospital databases. J Public Health. 2014;36(4):684–692.
   Web of Science ®Google Scholar
• Riscal R, Skuli N, Simon MC. Even cancer cells watch their cholesterol!. Mol Cell. 2019;76(2):220–231.
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ, McCarty MF. Is interleukin-6 the link between low LDL cholesterol and increased non-cardiovascular mortality in the elderly? Open Heart. 2018;5(1):e000789.
   PubMed Web of Science ®Google Scholar
• Kato H, Kinoshita T, Suzuki S, et al. Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 1998;29(1–2):71–79.
   PubMed Web of Science ®Google Scholar
• Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16(3):405–408.
   PubMed Web of Science ®Google Scholar
• Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104–116.
   PubMed Web of Science ®Google Scholar
• Gong IY, Cheung MC, Read S, et al. Association between diabetes and haematological malignancies: a population-based study. Diabetologia. 2021;64(3):540–551.
   PubMed Web of Science ®Google Scholar